The bwi product analysis lab received the device for evaluation on (b)(6) 2022.The device evaluation was completed on (b)(6) 2022.The product was returned to biosense webster for evaluation.Bwi then conducted a visual inspection and microscopic examination of the returned device.Visual analysis of the returned sample revealed that the hemostatic valve was dislodged inside the hub of the carto vizigo sheath.The valve separation could be related to the experienced obstruction.Examination of the shaft, the dilator, the brim cap, and the silicone ring revealed the components were placed in the correct position and found in good conditions.The functional test was performed, in accordance with biosense webster, inc.Procedures.After the hemostatic valve removal, the vessel dilator and smarttouch sf catheter were introduced into the vizigo sheath and no resistance was felt during the testing.The outer diameter vessel dilator was measured and it was within specifications.According to the odp (optimal performance guide), there are some precautions on inserting the dilator into the vizigo sheath: ¿always insert a dilator straight into the center of the sheath¿s valve to prevent damage to the valve.Do not insert a dilator at an angle, as damage to the sheath valve may occur.¿ a device history record evaluation was performed, and no internal actions related to the reported complaint condition were identified.As part of biosense webster's quality process, all devices are manufactured, inspected, and released to approved specifications.This product issue will be addressed through bwi's quality system.Manufacturer's reference number: (b)(4).
|
It was reported that a patient underwent an atrial fibrillation (afib) procedure with a carto vizigo¿ 8.5f bi-directional guiding sheath - medium and the biosense webster, inc.Product analysis lab observed a hemostatic valve separation issue.Initially, the dilator was unable to be advanced into the carto vizigo¿ 8.5f bi-directional guiding sheath - medium.The sheath was replaced and the issue resolved.There was no patient consequence reported.Additional information was received on the event.They met resistance while inserting the dilator into the sheath.There was no visible occlusion.The event was assessed as not mdr reportable for an obstructed sheath issue.The potential that it could cause or contribute to a death or serious injury, or other significant adverse event, was remote.The biosense webster, inc.Product analysis lab received the device for evaluation and per the evaluation completion on 25-jul-2022 the hemostatic valve was dislodged inside the hub of the carto vizigo sheath.The returned condition was assessed as mdr reportable for a hemostatic valve separation issue.The awareness date for this reportable lab finding was (b)(6) 2022.
|